Biblio

Filters: Author is Perales, Miguel-Angel [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, Jaimes EA, Perales M-A, Sathick IJaffer. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. Biol Blood Marrow Transplant. 2020.

Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020;4(16):3977-3989.

Cho C, Devlin S, Maloy M, Horowitz MM, Logan B, J Rizzo D, Giralt SA, Perales M-A. Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis. Bone Marrow Transplant. 2023.

Tamari R, Scordo M, Kunvarjee B, Proli A, Lin A, Flynn JR, Cho C, Devlin SM, Klein E, Boulad F, et al. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation. Blood Adv. 2023.

Hashmi H, Kumar A, Kharfan-Dabaja MA, Munshi PN, Inamoto Y, DeFilipp ZM, Dholaria B, Jain T, Perales M-A, Carpenter PA, et al. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy. Transplant Cell Ther. 2024.

Ahmed N, Kumar A, Kharfan-Dabaja MA, DeFilipp Z, Herrera A, Hashmi S, Dholaria B, Perales M-A, Carpenter PA, Hamadani M. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after failure of Chimeric antigen receptor T cell therapy (CAR-T) therapy. Transplant Cell Ther. 2022.

Fenske TS, Zhang M-J, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, et al. Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality. J Clin Oncol. 2013.

C

Mohty M, Duléry R, Gauthier J, Malard F, Brissot E, Aljurf M, Bazarbachi A, Chabanon C, Kharfan-Dabaja MA, Savani BN, et al. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant. 2020.

Tamari R, Chung S, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, Goldberg JD, Perales M-A, Ponce DM, Sauter CS, et al. CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and anti-thymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse. Biol Blood Marrow Transplant. 2015.

Krystel-Whittemore M, Petrova-Drus K, Ptashkin RN, Ewalt MD, Yao JJ, Liu Y, Zhu M, Benhamida J, Durham B, Kumar J, et al. Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies. Haematologica. 2024.

Blair LM, Akhund-Zade J, Katsamakis ZA, Smibert OC, Wolfe AE, Giardina P, Slingerland J, Bercovici S, Perales M-A, Taur Y, et al. Circulating microbial cell-free DNA is increased during neutropenia following hematopoietic stem cell transplantation. Blood Adv. 2023.

Sharma A, Bhatt NS, St Martin A, Abid MBilal, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales M-A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021.

Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg MLynne, Batlevi Y, Shouval R, Devlin SM, Batlevi C, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676-686.

Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, et al. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant. 2016.

Perales M-A, Kuruvilla J, Snider JThornton, Vadgama S, Blissett R, El-Moustaid F, Smith NJ, Patel A, Johnston P. The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: An economic evaluation of the ZUMA-7 trial. Transplant Cell Ther. 2022.

E

Sanchez-Escamilla M, Flynn J, Devlin S, Maloy M, Fatmi SA, Tomas AAlarcon, Escribano-Serrat S, Ponce D, Sauter CS, Giralt SA, et al. EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.

Ptashkin RN, Ewalt MD, Jayakumaran G, Kiecka I, Bowman AS, Yao JJ, Casanova J, Lin Y-TDavid, Petrova-Drus K, Mohanty AS, et al. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. Nat Commun. 2023;14(1):6895.

Montoro J, Ceberio I, Hilden P, Maloy MA, Barker J, Castro-Malaspina H, Dahi P, Koehne G, Perales M-A, Ponce D, et al. Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myeloid Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2019.

F

Perales M-A, Sauter C, Armand P. Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biol Blood Marrow Transplant. 2015.

Shah GL, DeWolf S, Lee YJoo, Tamari R, Dahi PB, Lavery JA, Ruiz JD, Devlin SM, Cho C, Peled JU, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020.

H

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, DeAngelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, et al. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019.

Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SOctavian, Holtzman NG, Ii GLPhillips, Devine SM, et al. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.

Shah N, Dahi PB, Ponce DM, Sauter CS, Shaffer BC, Chung DJ, Politikos I, Lin RJ, Giralt SA, Papanicolaou G, et al. HEMATOPOIETIC CELL TRANSPLANTATION IS FEASIBLE IN PATIENTS WITH PRIOR COVID-19 INFECTION. Transplant Cell Ther. 2021.

Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, et al. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the ASBMT. Biol Blood Marrow Transplant. 2015.

I

Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, et al. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Transplant Cell Ther. 2023.

Pages